NCT03263507View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Donidalorsen (IONIS-PKK-LRx) Administered Subcutaneously to Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 28, 2017

Primary Completion Date

October 9, 2018

Study Completion Date

October 9, 2018

Conditions
Healthy Volunteers
Interventions
DRUG

Placebo

Saline .9%

DRUG

Donidalorsen

Donidalorsen administered subcutaneously

Trial Locations (1)

M9L 3A2

Ionis Investigative Site, Toronto

Sponsors
All Listed Sponsors
lead

Ionis Pharmaceuticals, Inc.

INDUSTRY